Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Leases (2023 - 2025)

China SXT Pharmaceuticals has reported Current Leases over the past 3 years, most recently at $64118.0 for Q3 2025.

  • For Q3 2025, Current Leases rose 110.91% year-over-year to $64118.0; the TTM value through Sep 2025 reached $64118.0, up 110.91%, while the annual FY2025 figure was $61229.0, 5.01% up from the prior year.
  • Current Leases for Q3 2025 was $64118.0 at China SXT Pharmaceuticals, up from $61229.0 in the prior quarter.
  • Over five years, Current Leases peaked at $64118.0 in Q3 2025 and troughed at $30401.0 in Q3 2024.
  • A 3-year average of $54719.7 and a median of $58199.5 in 2023 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: tumbled 45.88% in 2024 and later surged 110.91% in 2025.
  • Year by year, Current Leases stood at $56171.0 in 2023, then tumbled by 45.88% to $30401.0 in 2024, then skyrocketed by 110.91% to $64118.0 in 2025.
  • Business Quant data shows Current Leases for SXTC at $64118.0 in Q3 2025, $61229.0 in Q1 2025, and $30401.0 in Q3 2024.